Cold-Adapted Pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against Seasonal and H5 influenza A viruses

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5953-5958

  Jang, Yo Han ^a   Byun, Young Ho ^a   Lee, Yoon Jae ^a   Lee, Yun Ha ^a   Lee, Kwang Hee ^a   Seong, Baik Lin ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE;

ANTIBODY TITER; ARTICLE; COLD ACCLIMATIZATION; CROSS REACTION; DISEASE SEVERITY; GENETIC REASSORTMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H5N2; LETHALITY; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADAPTATION, BIOLOGICAL; ANIMALS; COLD TEMPERATURE; CROSS REACTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PANDEMICS; REPUBLIC OF KOREA; SEASONS; VACCINES, ATTENUATED;

AVES; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84861302929     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07149-11     Document Type: Article

References (44)

1. Alam S, Sant AJ. 2011. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J. Virol. 85:13310-13321.
2. Belshe RB, et al. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181:1133-1137.
3. Benton KA, et al. 2001. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or γδ T cells. J. Immunol. 166:7437-7445.
4. Berhane Y, et al. 2010. Molecular characterization of pandemic H1N1 influenza viruses isolated from turkeys and pathogenicity of a human pH1N1 isolate in turkeys. Avian Dis. 54:1275-1285.
5. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181:4168-4176.
6. Chen GL, Lau Y-F, Lamirande EW, McCall AW, Subbarao K. 2011. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc. Natl. Acad. Sci. U. S. A. 108:1140-1145.
7. Chen GL, et al. 2011. Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J. Infect. Dis. 203:930-936.
8. Chen L-M, Davis CT, Zhou H, Cox NJ, Donis RO. 2008. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 4:e1000072.
9. Chen Z, Kim L, Subbarao K, Jin H. 2012. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30:2516-2522.
10. Chen Z, et al. 2010. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 84:44-51.
11. Corti D, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.
12. Edwards KM, et al. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenzaAdisease. J. Infect. Dis. 169:68-76.
13. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
14. Fang Y, et al. 2012. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8- independent, B cell-dependent mechanism. J. Virol. 86:2229-2238.
15. Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS. 2011. Report of the 7th meeting on evaluation of pandemic influenza vaccines in clinical trials, World Health Organization, Geneva, 17-18 February 2011. Vaccine29:7579-7586.
16. Gocník M, et al. 2008. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J. Gen. Virol. 89:958-967.
17. Gocník M, et al. 2007. Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol. 88:951-955.
18. Gorse GJ, Belshe RB. 1991. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with liveattenuated viruses. Scand. J. Infect. Dis. 23:7-17.
19. Gorse GJ, et al. 1995. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J. Infect. Dis. 172:1-10.
20. Herfst S, et al. 2010. Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission. J. Virol. 84:3752-3758.
21. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. 2001. Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166:7381-7388.
22. Ichinohe T, Iwasaki A, Hasegawa H. 2008. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev. Vaccines 7:1435-1445.
23. Joseph T, et al. 2008. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378:123-132.
24. Krause JC, et al. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85:10905-10908.
25. Lee K-H, et al. 2006. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine 24:1966-1974.
26. Octaviani CP, Li C, Noda T, Kawaoka Y. 2011. Reassortment between seasonal and swine-origin H1N1 influenza viruses generates viruses with enhanced growth capability in cell culture. Virus Res. 156:147-150.
27. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. 2010. High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84:10918-10922.
28. Prabhu N, et al. 2009. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83:2553-2562.
29. Qiu C, et al. 2012. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin. Infect. Dis. 54:17-24.
30. Rangel-Moreno J, et al. 2008. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 180:454-463.
31. Shi J, et al. 2012. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antiviral Res. 93:346-353.
32. Song M-S, et al. 2009. The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model. J. Virol. 83:12325-12335.
33. Staneková Z, Vareckova E. 2010. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 7:351.
34. Suguitan AL, Jr et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360.
35. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
36. Sun K, Ye J, Perez DR, Metzger DW. 2011. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J. Immunol. 186:987-993.
37. Tamura SI, Tanimoto T, Kurata T. 2005. Mechanisms of broad crossprotection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58:195-207.
38. Tan PT, Khan AM, August JT. 2011. Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum. Vaccin. 7:402-409.
39. Van Reeth K, et al. 2009. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenicH5N1avian influenza virus. Vaccine 27:6330-6339.
40. Weinfurter JT, et al. 2011. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog. 7:e1002381.
41. Whittle JRR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216-14221.
42. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
43. Xie H, et al. 2009. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. J. Infect. Dis. 200:1874-1883.
44. Yang P, et al. 2011. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemicAH1N1 in mice and ferrets. Vaccine 29:698-705.